Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis

Bevacizumab has demonstrated a survival benefit in patients with metastatic colorectal cancer (mCRC) when combined with chemotherapy. Several randomized clinical trials comparing the efficacy and toxicity of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) agains...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Clin Oncol
Autori principali: LIN, ZEXIN, YANG, YILIN, HUANG, YONGLIANG, LIANG, JUNJIE, LU, FANG, LAO, XUEJUN
Natura: Artigo
Lingua:Inglês
Pubblicazione: D.A. Spandidos 2015
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4486826/
https://ncbi.nlm.nih.gov/pubmed/26171215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.572
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi